

Mozambique **Support for Pneumococcal Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1.	Country:	Country: Mozambique						
2.	Grant number: 1819-MOZ-12d-X; 12-MOZ-08a-Y; 17-MOZ-25a-Y							
3.	Date of Decision Letter: 21 December 2017							
4.	Date of the Partnership Framework Agreement: 06 December 2013							
5.	Programme title: New Vaccine Support (NVS), Pneumococcal Routine							
6.	Vaccine type: Pneumococcal							
7.	Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID							
8.	Programme duration ¹ : 2013 - 2019							
9.	Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)							
		2013-2017	2018	2019	Total ²			
Programme Budget (US\$)		US\$75,214,231 ³	US\$10,210,500	US\$11,665,500	US\$97,090,231			
10. Vaccine introduction grant / Product switch grant: Vaccine introduction grant of US\$373,147 was disbursed on 19 March 2013 and US\$ 442,353 on 10 April 2013. Return of US\$ 23,199 unused funds on 21 June 2016. Product Switch Grant of US\$292,000 out of which 271,286 disbursed on 05 July 2017.								
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement ⁴								
Type of supplies to be purchased		2013-20	17	2018				
with Gavi funds in each year								

12. Procurement agency: UNICEF. The Country shall release its co-financing
payments each year to UNICEF.

US\$75,214,231⁵

13. Self-procurement: Not applicable.

Number of Pneumococcal vaccines

Annual Amounts (US\$)

doses

2 Chemin des Mines 1202 Geneva. Switzerland Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50

3,041,000

US\$10,210,500

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



14. Co-financing obligations: Reference code: 1819-MOZ-12d-X-C

According to the co-financing policy, the Country falls within the group Initial selffinancing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

• • • • • • • • • • • • • • • • • • •		
Type of supplies to be	2018	2019
purchased with Country funds in		
each year		
Number of vaccine doses	212,200	232,800
Value of vaccine doses (US\$)	US\$646,737	
Total co-financing payments	US\$651,000	US\$714,000
(US\$) (including freight)		

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions:

The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard

Signed by,

On behalf of Gavi

Third A. Thath

Hind Khatib-Othman Managing Director, Country Programmes

21 December 2017